Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2011

Open Access 01-12-2011 | Research article

Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study

Authors: Heather F Gidding, Gregory J Dore, Janaki Amin, Matthew G Law

Published in: BMC Public Health | Issue 1/2011

Login to get access

Abstract

Background

Previous studies have reported an excess burden of cancer and mortality in populations with chronic hepatitis B (HBV) or C (HCV), but there are limited data comparing hospitalization rates. In this study, we compared hospitalization rates for all causes and viral liver disease in people notified with HBV or HCV in New South Wales (NSW), Australia.

Methods

HBV and HCV notifications were linked to their hospital (July 2000-June 2006), HIV and death records. Standardized hospitalization ratios (SHRs) were calculated using rates for the NSW population. Random effects Poisson regression was used to examine temporal trends.

Results

The SHR for all causes and non alcoholic liver disease was two-fold higher in the HCV cohort compared with the HBV cohort (SHRs 1.4 (95%CI: 1.4-1.4) v 0.6 (95%CI: 0.6-0.6) and 14.0 (95%CI: 12.7-15.4) v 5.4 (95%CI: 4.5-6.4), respectively), whilst the opposite was seen for primary liver cancer (SHRs 16.2 (95%CI: 13.8-19.1) v 29.1 (95%CI: 24.7-34.2)). HIV co-infection doubled the SHR except for primary liver cancer in the HCV/HIV cohort. In HBV and HCV mono-infected cohorts, all cause hospitalization rates declined and primary liver cancer rates increased, whilst rates for non alcoholic liver disease increased by 9% in the HCV cohort but decreased by 14% in the HBV cohort (P < 0.001).

Conclusion

Hospital-related morbidity overall and for non alcoholic liver disease was considerably higher for HCV than HBV. Improved treatment of advanced HBV-related liver disease may explain why HBV liver-related morbidity declined. In contrast, HCV liver-related morbidity increased and improved treatments, especially for advanced liver disease, and higher levels of treatment uptake are required to reverse this trend.
Appendix
Available only for authorised users
Literature
1.
Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG: Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol. 2006, 45 (2): 197-203. 10.1016/j.jhep.2006.02.014.CrossRefPubMed
2.
Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ: Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006, 368 (9539): 938-945. 10.1016/S0140-6736(06)69374-4.CrossRefPubMed
3.
Duberg A-S, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A, Hultcrantz R, Back E, Ekdahl K: Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008, 15 (7): 538-550. 10.1111/j.1365-2893.2008.00982.x.CrossRefPubMed
4.
McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, Robertson C, Donaghy M, Hayes P, Graham L, Goldberg DJ: A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res. 2009, 18 (3): 271-283. 10.1177/0962280208094690.CrossRefPubMed
5.
McDonald SA, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Dillon JF, Goldberg DJ: A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer. 2008, 99 (5): 805-810. 10.1038/sj.bjc.6604563.CrossRefPubMedPubMedCentral
6.
Omland LH, Jepsen P, Skinhoj P, Jorgensen HL, Munster AMB, Bangsborg J, Fenger M, Sorensen HT, Obel N: The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study. HIV Medicine. 2009, 10 (2): 65-71. 10.1111/j.1468-1293.2008.00652.x.CrossRefPubMed
7.
Steinke DT, Weston TL, Morris AD, MacDonald TM, Dillon JF: Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut. 2002, 50 (1): 100-105. 10.1136/gut.50.1.100.CrossRefPubMedPubMedCentral
8.
Chang T-T, Lai C-L, Kew Yoon S, Lee SS, Coelho HSM, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010, 51 (2): 422-430.CrossRefPubMed
9.
Liaw Y-F, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han S-H, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, The Globe Study Group: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009, 136 (2): 486-495. 10.1053/j.gastro.2008.10.026.CrossRefPubMed
10.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008, 359 (23): 2442-2455. 10.1056/NEJMoa0802878.CrossRefPubMed
11.
Chang T-T, Liaw Y-F, Wu S-S, Schiff E, Han K-H, Lai C-L, Safadi R, Lee SS, Halota W, Goodman Z, Chi Y-C, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010, 52 (3): 886-893. 10.1002/hep.23785.CrossRefPubMed
12.
Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee C-Z, Yuen H, Tanwandee T, Tao Q-M, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004, 351 (15): 1521-1531. 10.1056/NEJMoa033364.CrossRefPubMed
13.
Matthews GV, Cooper DA, Dore GJ: Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antiviral Therapy. 2007, 12 (1): 119-122.PubMed
14.
Schiff ER, Lai C-L, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve J-P, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL, The Adefovir Dipovoxil Study 435 International Investigators Group: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003, 38 (6): 1419-1427.PubMed
15.
Population Health Division: The health of the people of New South Wales - Report of the Chief Health Officer. 2009, Sydney: NSW Department of Health
16.
McDonald AM, Crofts N, Kaldor JM, National HIV Surveillance Committee: A national surveillance system for newly acquired HIV infection in Australia. Am J Public Health. 1994, 84 (12): 1923-1928. 10.2105/AJPH.84.12.1923.CrossRefPubMedPubMedCentral
17.
Kaldor J, McDonald AM, Blumer CE, Gertig DM, Patten JJ, Roberts M, Walker CC, Mullins SE, Bailey KA, Chuah JCP: The acquired immunodeficiency syndrome in Australia: incidence 1982 - 1991. Med J Aust. 1993, 158: 10-17.PubMed
18.
19.
ChoiceMaker Technologies Inc: New York, NY10010.
20.
Stukel TA, Glynn RJ, Fisher ES, Sharp SM, Lu-Yao G, Wennberg JE: Standardized rates of recurrent outcomes. Stat Med. 1994, 13 (17): 1781-1791. 10.1002/sim.4780131709.CrossRefPubMed
21.
Kirkwood BR, Sterne JAC: Essential medical statistics. 2003, Malden, Massachusetts: Blackwell Science Ltd, 2
22.
Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore GJ, George J, Kaldor JM, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M: Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007, 91 (2-3): 228-235. 10.1016/j.drugalcdep.2007.05.026.CrossRefPubMed
23.
O'Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ: Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust NZ J Public Health. 2004, 28 (3): 212-216.CrossRef
24.
Gidding HF, Amin J, Dore GJ, Ward K, Law MG: Hospital-related morbidity in people notified with hepatitis C; a population-based record linkage study in New South Wales, Australia. J Hepatol. 2010, 53: 43-49. 10.1016/j.jhep.2010.01.036.CrossRefPubMed
25.
Singh GK, Siahpush M: Ethnic-immigrant differentials in health behaviors, morbidity, and cause-specific mortality in the United States: an analysis of two national data bases. Hum Biol. 2002, 74 (1): 83-109. 10.1353/hub.2002.0011.CrossRefPubMed
26.
Thein H-H, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008, 48 (2): 418-431. 10.1002/hep.22375.CrossRefPubMed
27.
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001, 34 (5): 730-739. 10.1016/S0168-8278(00)00097-0.CrossRefPubMed
28.
Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J, Risk Evaluation of Viral Load E, Associated Liver Disease/Cancer-In HBVSG: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006, 130 (3): 678-686. 10.1053/j.gastro.2005.11.016.CrossRefPubMed
29.
Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T, The Multivirc Group: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999, 30 (4): 1054-1058. 10.1002/hep.510300409.CrossRefPubMed
30.
Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NLC, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A: End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002, 100 (5): 1584-1589.PubMed
31.
Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F: Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000, 32 (5): 1106-1110. 10.1053/jhep.2000.19288.CrossRefPubMed
32.
Thein H-H, Yi Q, Dore GJ, Krahn MD: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008, 22 (15): 1979-1991. 10.1097/QAD.0b013e32830e6d51.CrossRefPubMed
33.
Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998, 28 (1): 27-33. 10.1016/S0168-8278(98)80198-0.CrossRefPubMed
34.
Bodsworth N, Donovan B, Nightingale BN: The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis. 1989, 160 (4): 577-582.CrossRefPubMed
35.
Puoti M, Torti C, Bruno R, Filice G, Carosi G: Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006, 44 (1 Suppl): S65-70. 10.1016/j.jhep.2005.11.015.CrossRefPubMed
36.
Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, Precone D, Gelatti U, Asensi V, Vaccher E, Group HHCI-S: Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004, 18 (17): 2285-2293. 10.1097/00002030-200411190-00009.CrossRefPubMed
37.
Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G, Maher L, Kaldor JM, Dore GJ, Law MG: The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006. J Gast Hepatol. 2009, 24 (10): 1648-1654. 10.1111/j.1440-1746.2009.05910.x.CrossRef
38.
National Centre in HIV Epidemiology and Clinical Research: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. 2009, University of NSW, Sydney
39.
Cheng WSC, Roberts S, Weltman M, Crawford DHG, Sievert W, McCaughan G, Rawlinson W, Desmond P, Yoshihara M, Rizkalla B, DePamphilis J, Marks P, Dore GJ: Efficacy and safety of Peginterferon alfa-2A 360 μg/week in combination with ribavirin in hepatitis C genotype 1 patients with cirrhosis: analysis from the CHARIOT study. J Hepatol. 2009, 50: S221-10.1016/S0168-8278(09)60603-6.CrossRef
40.
Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, Study T, Study T: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004, 189 (7): 1185-1192. 10.1086/380398.CrossRefPubMed
41.
Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL: Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009, 137 (5): 1680-1686. 10.1053/j.gastro.2009.07.047.CrossRefPubMedPubMedCentral
42.
Walter SR, Thein H-H, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ: Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol. 2010,
43.
Amin J, O'Connell D, Bartlett M, Tracey E, Kaldor J, Law M, Dore G: Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. Aust NZ J Public Health. 2007, 31 (5): 475-482. 10.1111/j.1753-6405.2007.00121.x.CrossRef
44.
Alam N, Chen W, Baker D, Bishop J: Liver Cancer in New South Wales Sydney. 2009, Cancer Institute NSW
45.
Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ: Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005, 129 (2): 486-493.CrossRefPubMed
46.
Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127 (5 Suppl 1): S35-50. 10.1053/j.gastro.2004.09.014.CrossRefPubMed
47.
Blum HE, Moradpour D: Viral pathogenesis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2002, 17 (Suppl 3): S413-420. 10.1046/j.1440-1746.17.s3.37.x.CrossRefPubMed
48.
Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL: Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology. 2005, 42 (6): 1406-1413. 10.1002/hep.20941.CrossRefPubMed
49.
Myers RP, Liu M, Shaheen AA: The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol. 2008, 22 (4): 381-387.CrossRefPubMedPubMedCentral
50.
Thomson SJ, Westlake S, Rahman TM, Cowan ML, Majeed A, Maxwell JD, Kang J-Y: Chronic liver disease--an increasing problem: a study of hospital admission and mortality rates in England, 1979-2005, with particular reference to alcoholic liver disease. Alcohol Alcohol. 2008, 43 (4): 416-422.CrossRefPubMed
51.
Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006, 13 (1): 34-41. 10.1111/j.1365-2893.2005.00651.x.CrossRefPubMed
Metadata
Title
Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study
Authors
Heather F Gidding
Gregory J Dore
Janaki Amin
Matthew G Law
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2011
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-11-52

Other articles of this Issue 1/2011

BMC Public Health 1/2011 Go to the issue

Research article

Male commuters in north and south England: risk factors for the presence of faecal bacteria on hands

Research article

Racism and health among urban Aboriginal young people

Research article

Selected sociodemographic factors and related differences in patterns of alcohol use among university students in Slovakia

Research article

Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study

Study protocol

The impact and process of a community-led intervention on reducing environmental inequalities related to physical activity and healthy eating - a pilot study

Research article

Behaviour patterns preceding a railway suicide: Explorative study of German Federal Police officers' experiences